|
AU6407099A
|
|
Methods for the treatment of non-thyroid disorders
|
|
AU6277899A
|
|
Null IGF for the treatment of cancer
|
|
US7288516B1
|
|
Null IGF for the treatment of cancer
|
|
US6040292A
|
|
Methods for treating diabetes
|
|
US6417330B1
|
|
Insulin-like growth factor binding protein variants
|
|
US6087090A
|
|
Methods for predicting drug response
|
|
US6514937B1
|
|
Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
|
|
US6436897B2
|
|
Pharmaceutical formulations for IGF/IGFBP
|
|
US6124259A
|
|
Method for treating ophthalmic disorders with IGFBP
|
|
AU4097797A
|
|
Biologically active TGF-beta1 and TGF-beta2 peptides
|
|
US5914254A
|
|
Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
|
|
US5914390A
|
|
Methods for increasing yields of recombinant proteins
|
|
US6015786A
|
|
Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
|
|
US6025368A
|
|
Method for treating the symptoms of chronic stress-related disorders using IGF
|
|
US5824467A
|
|
Methods for predicting drug response
|
|
US5767079A
|
|
Method of treating ophthalmic disorders using TGF -β
|
|
PL323746A1
|
|
Chromosomal expression of heterogenous genes in bacterial cells
|
|
US5948757A
|
|
High dose IGF-1 therapy
|
|
WO9609838A1
|
|
METHOD OF TREATING MACULAR DEGENERATION USING TGF-$g(b)
|
|
AU3099995A
|
|
IGF/IGFBP complex for promoting bone formation and for regulating bone remodeling
|
